Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048417 | 0.88 | DRD2 (0.50) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL1047301 | 0.86 | MEN1 (0.51) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL9114592 | 0.85 | CYP1A2 (0.63) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL1043782 | 0.85 | MEN1 (0.54) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL10338308 | 0.82 | MEN1 (0.60) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL316199 | 0.80 | MAOB (0.47) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL1620167 | 0.78 | APP (0.52) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL6475216 | 0.76 | KDM4E (0.48) | L3MBTL1DRD2DRD4DRD3LTA4H | |
| SCHEMBL5248320 | 0.76 | DRD2 (0.52) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 | |
| SCHEMBL167606 | 0.76 | DRD2 (0.56) | CYP1A2CYP2D6CYP2C19TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113195450-B | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2024-04-26 | — | — | CN | claimed |
| CN-113227045-B | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2024-04-26 | — | — | CN | claimed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | claimed |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2022-03-03 | — | — | US | claimed |
| EP-3897621-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| EP-3898581-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| EP-3898580-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2021-10-27 | — | — | EP | claimed |
| CN-113227045-A | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2021-08-06 | — | — | CN | claimed |
| CN-113195450-A | Synthesis of substituted heterocycle fused gamma-carbolines | 细胞内治疗公司 | 2021-07-30 | — | — | CN | claimed |
| CN-108084179-B | Compound with spiro structure, preparation method and application thereof | 上海医药工业研究院 | 2021-02-05 | — | — | CN | claimed |
| WO-2002024701-A2 | SUBSTITUTED AZEPINO[4,5B)INDOLE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| WO-2002024700-A2 | SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| CN-1313857-A | Process for the synthesis of substituted tetrahydrofuran compounds | LEUKOSITE INC (US) | 2001-09-19 | — | — | CN | claimed |
| WO-2001004118-A2 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR LIGANDS | ALMIRALL PRODESFARMA S.A. (ES) | 2001-01-18 | — | — | WO | claimed |
| CN-1233240-A | Synthesis method of cisapride | JANSSEN PHARMACEUTICA NV (BE) | 1999-10-27 | — | — | CN | claimed |
| EP-0934272-A1 | SYNTHESIS OF CISAPRIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-08-11 | — | — | EP | claimed |
| US-5783702-A | Preparation of cisapride | TORCAN CHEMICAL LTD. (CA) | 1998-07-21 | — | — | US | claimed |
| WO-1998016511-A1 | SYNTHESIS OF CISAPRIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-23 | — | — | WO | claimed |
| US-5585387-A | Prepration of cisapride | TORCAN CHEMICAL LTD. (CA) | 1996-12-17 | — | — | US | claimed |
| WO-1996011186-A1 | PREPARATION OF CISAPRIDE | TORCAN CHEMICAL LTD. (CA) | 1996-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | CYP1A2 139/4885CYP2D6 1563/4885CYP2C19 478/4885 |
| US-20220064166-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | CYP1A2 139/4885CYP2D6 1563/4885CYP2C19 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.